Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
2-hydroxybenzylamine (2-HOBA) is a naturally occurring small molecule found in Himalayan tartary buckwheat and other sources. It acts as a potent scavenger of reactive carbonyl species, particularly γ-ketoaldehydes (γKAs) and isolevuglandins (IsoLGs), which are highly reactive products of lipid peroxidation implicated in oxidative stress-related cellular damage. By rapidly reacting with these electrophiles, 2-HOBA prevents their covalent modification of proteins, nucleic acids, and phospholipids—thereby reducing inflammation, promoting plaque stability in atherosclerosis models, protecting cardiac sodium channels from oxidant-induced inactivation, and potentially mitigating cognitive decline associated with conditions like Alzheimer's disease. It has demonstrated safety in animal studies and Phase I clinical trials. The compound is available as an over-the-counter dietary supplement under the brand name Hobamine and has been investigated for use in atrial fibrillation recurrence prevention post-ablation, rheumatoid arthritis, familial hypercholesterolemia, hypertension-related vascular injury, gastric cancer chemoprevention (especially related to H. pylori infection), and neurodegenerative diseases[1][3][4][6][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 2-hydroxybenzylamine.